Mace

(redirected from Major Adverse Cardiovascular Events)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.

Mace

A unit of weight in Taiwan approximately equivalent to 3.75 grams. It is used primarily in the sale of bulk foodstuffs.
References in periodicals archive ?
Brilinta, together with aspirin, has been shown to significantly reduce the risk of major adverse cardiovascular events (myocardial infarction, stroke or CV death) in patients with acute coronary syndrome (ACS) or a history of MI.
inhibitor dapagliflozin reduced risks of 119.03999 both major adverse cardiovascular events and heart failure hospitalization in the subset of 3,584 patients with type 2 diabetes and prior myocardial infarction versus controls.
They found the incidence of major adverse cardiovascular events was the same among patients taking vitamin D supplements and those taking placebo (risk ratio, 1; P = .85).
The topic of his poster was Comparisons of one year major adverse cardiovascular events in patients undergoing PCI versus CABG with underlying Chronic Kidney Disease (Creatinine clearance <30).
The primary safety objective was to evaluate the incidence of major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction or stroke.
Patients were followed-up from 2000 to 2016 for the occurrence of major adverse cardiovascular events such as as heart attack, stroke, and death from cardiovascular causes.
The main secondary endpoint of major adverse cardiovascular events requiring hospitalization was also significantly reduced from 40.4 per 1000 patient years in the control group to 22.3 per 1000 patient years in the intervention group (Fig.
The prespecified primary endpoints for TIMI's safety analysis included new-onset atrial flutter or atrial fibrillation, as well as a composite endpoint of major adverse cardiovascular events (MACE), defined as myocardial infarction, stroke, or cardiovascular death.
Evolocumab-treated subjects were less likely to experience "all cardiovascular events", and major adverse cardiovascular events at one year (hazard ratio 0.47; 95% CI 0.28-0.78 for both).
The rate of major adverse cardiovascular events, such as stroke or heart attack, is relatively low among patients who experience hypertensive urgency.
Major adverse cardiovascular events (MACE) of concern occurred in 1 patient treated with naldemedine and 1 in the placebo group.
Full browser ?